Acalabrutinib Monotherapy in Patients With Ibrutinib Intolerance: Results From the Phase 1/2 ACE-CL-001 Clinical Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 16
页数：3
相关论文
共 50 条
  • [41] Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis: Results From the ACE-536-MF-001 Study
    Gerds, Aaron T.
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Mesa, Ruben
    Vannucchi, Alessandro M.
    Komrokji, Rami
    Bose, Prithviraj
    Kremyanskaya, Marina
    Mead, Adam J.
    Gotlib, Jason
    Sanabria, Fabian
    Marsousi, Niloufar
    Giuseppi, Ana Carolina
    Jiang, Huijing
    Palmer, Jeanne M.
    McCaul, Kelly
    Ribrag, Vincent
    Passamonti, Francesco
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S393 - S393
  • [42] ADDITIONAL RESULTS FROM A PHASE 1B STUDY OF IGV-001 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Perez-Olle, Raul
    Pennock, Gregory
    Scott, Charles
    Hooper, D. Craig
    Judy, Kevin
    Andrews, David
    NEURO-ONCOLOGY, 2023, 25
  • [43] Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study
    Jones, Jeffrey
    Andritsos, Leslie
    Kreitman, Robert J.
    Ravandi, Farhad
    Schiffer, Charles
    Call, Timothy G.
    Lozanski, Gerard
    Harris, Pamela
    Sexton, Jennifer
    Ruppert, Amy S.
    Grever, Michael R.
    BLOOD, 2016, 128 (22)
  • [44] A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
    Collins, Graham P.
    Clevenger, Tracy N.
    Burke, Kathleen A.
    Yang, Buyue
    MacDonald, Alex
    Cunningham, David
    Fox, Christopher P.
    Goy, Andre
    Gribben, John
    Nowakowski, Grzegorz S.
    Roschewski, Mark
    Vose, Julie M.
    Vallurupalli, Anusha
    Cheung, Jean
    Raymond, Amelia
    Nuttall, Barrett
    Stetson, Dan
    Dougherty, Brian A.
    Schalkwijk, Stein
    Carnevalli, Larissa S.
    Willis, Brandon
    Tao, Lin
    Harrington, Elizabeth A.
    Hamdy, Ahmed
    Izumi, Raquel
    Pease, J. Elizabeth
    Frigault, Melanie M.
    Flinn, Ian
    LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2625 - 2636
  • [45] Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study (vol 7, pg e112, 2020)
    Owen, R. G.
    McCarthy, H.
    Rule, S.
    LANCET HAEMATOLOGY, 2021, 8 (04): : E249 - E249
  • [46] Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study
    Carpenter, Paul A.
    Kang, Hyoung Jin
    Yoo, Keon Hee
    Zecca, Marco
    Cho, Bin
    Lucchini, Giovanna
    Nemecek, Eneida R.
    Schultz, Kirk R.
    Stepensky, Polina
    Chaudhury, Sonali
    Oshrine, Benjamin
    Khaw, Seong Lin
    Harris, Andrew C.
    Verna, Marta
    Zubarovskaya, Liudmila
    Lee, Yihua
    Wahlstrom, Justin
    Styles, Lori
    Shaw, Peter J.
    Dalle, Jean-Hugues
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (11): : 771.e1 - 771.e10
  • [47] Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study
    Rogers, Kerry A.
    Flinn, Ian W.
    Stephens, Deborah M.
    Kipps, Thomas J.
    Larson, Sarah
    McGarry, Carolyn
    Hassounah, Nadia B.
    Gou, Liangke Connie
    Woo, Janghee
    Byrd, John C.
    BLOOD, 2021, 138
  • [48] Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
    Gerds, Aaron Thomas
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Mesa, Ruben A.
    Vannucchi, Alessandro M.
    Komrokji, Rami S.
    Bose, Prithviraj
    Kremyanskaya, Marina
    Mead, Adam J.
    Gotlib, Jason R.
    Sanabria, Fabian
    Marsousi, Niloufar
    Giuseppi, Ana Carolina
    Jiang, Huijing
    Palmer, Jeanne M.
    McCaul, Kelly
    Ribrag, Vincent
    Verstovsek, Srdan
    Passamonti, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Jurczak, Wojciech
    Elmusharaf, Nagah
    Fox, Christopher P.
    Townsend, William
    Paulovich, Amanda G.
    Sharma, Shringi
    Parr, Graeme
    Munugalavadla, Veerendra
    Krantz, Fanny
    Yang, Helen
    Dean, Emma
    Manwani, Richa
    Hillmen, Peter
    CANCER RESEARCH, 2022, 82 (12)
  • [50] Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
    Herling, Marco
    Dearden, Claire
    Zaja, Francesco
    El-Sharkawi, Dima
    Ding, Wei
    Bellido, Mar
    Khot, Amit
    Tick, Lidwine
    Jacobsen, Eric
    Eyre, Toby A.
    Roos-Weil, Damien
    Kadia, Tapan
    Lucchini, Elisa
    Pflug, Natali
    Davids, Matthew S.
    Pena, German
    Mukherjee, Nabanita
    Badawi, Mohamed
    Vizkelety, Tamas
    Staber, Philipp B.
    BLOOD ADVANCES, 2024, 8 (04) : 842 - 845
12345